Simultaneous multivessel acute drug-eluting stent thrombosis

International Journal of Cardiology

Volumn 113, Issue 1, 2006, Pages

  Garcia, Joel A ^a,b   Hansgen, Adam ^a,b   Casserly, Ivan P ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome (ACS); Drug eluting stents (DES); Percutaneous coronary intervention (PCI); Stent thrombosis (ST)

Indexed keywords

ANTITHROMBOCYTIC AGENT; PACLITAXEL;

ADULT; ARTICLE; CASE REPORT; DRUG ELUTING STENT; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; PRIORITY JOURNAL; RIGHT CORONARY ARTERY; THROMBOCYTE; THROMBOSIS;

CORONARY THROMBOSIS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; STENTS; TIME FACTORS;

EID: 33750452332     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.01.073     Document Type: Article

References (7)

1. Kandzari D.E., Berger P.B., et al., for the ISAR-REACT Study investigators. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 44 (2004) 2133-2136
2. Mehilli J., Kastrati A., Schulen H., et al., for the Intracoronary Stenting and Antithrombotic Regimen: Is abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110 (2004) 3627-3635
3. Yusuf S., Zhao F., Mehta S.R., et al., for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
4. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358 (2001) 527-533
5. Hamm C.W., Heeschen C., Goldmann B., et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. C7E3 Fab antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 340 (1999) 1623-1629
6. Lenderinnk T., Boersma E., Heeschen C., et al. Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, an troponin T predicts benefit of treatment with abciximab in combination with PTCA. Eur Heart J 24 (2003) 136-137
7. Heeschen C., Hamm C.W., Goldmann B., et al. Troponin concentration for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of Tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 354 (1999) 1757-1762